Taken together, caution should be taken when treating cancer patients with JAK-STAT inhibitors, especially when combining them with immunotherapy, since systemic targeting of the JAK-STAT pathway can have divergent effects on tumor growth and anti-tumor immune responses. The gene discussed is SOAT1; the disease is cancer.